Assessment of retinoblastoma treatment by ophthalmic artery chemotherapy
Main Article Content
Abstract
Chemotherapy through the ophthalmic artery is significant in the treatment of vision preservation as well as the survival time of patients with retinoblastoma (UNBVM). This is a cross-sectional descriptive study on 27 patients (16 men and 11 women) diagnosed with UNBVM and indicated for ophthalmic arterial chemotherapy from October 2019 to October 2021. Imaging characteristics of retinoblastoma on ultrasound and magnetic resonance imaging are described and the results of treatment of retinoblastoma patients with ophthalmic arterial chemotherapy. On ultrasound, 9/27 tumors were detected with calcifications, representing 23.4% of total tumors. On MRI, 5/25 tumors were detected with calcifications, representing 13.5% of total tumors. The detection rate on magnetic resonance imaging/number of patients was 85%. 97% of patients used Melphalan alone, 3% used a mixture of Carboplatin, Topotecan, Alkeran. At 3, 6, and 9 months, we monitored 100% of the patients (30 eyes), in which the preserved eye accounted for 76.7%, 70% and 66.7%, respectively. After 12 months, 58.6% of eyes were preserved out of a total of 29 eyes that were followed up, and 1 eye had not had enough follow-up time. After 15 months, 55.6% of eyes were preserved out of 27 eyes followed, 2 eyes had not enough follow-up time. After 18 months, 41.7% of eyes were preserved out of 27 eyes that were followed up, 3 eyes did not have enough follow-up time.
Article Details
Keywords
retinoblastoma, ophthalmic artery chemotherapy
References
2. Xu XL, Fang Y, Lee TC, et al. Retinoblastoma has properties of a cone precursor tumor and depends upon cone-specific MDM2 signaling. Cell. 2009;137(6):1018-1031. doi:doi:10.1016/j.cell.2009.03.051
3. Seregard S, Lundell G, Svedberg H, Kivelä T. Incidence of retinoblastoma from 1958 to 1998 in Northern Europe: advantages of birth cohort analysis. Ophthalmology. 2004;111(6):1228-1232. doi:doi:10.1016/j.ophtha.2003.10.023
4. Moll AC, Kuik DJ, Bouter LM, et al. Incidence and survival of retinoblastoma in The Netherlands: a register based study 1862-1995. Br J Ophthalmol. 1997;81(7):559-562. doi:doi:10.1136/bjo.81.7.559
5. Nguyễn Chấn Hùng. Một vài khía cạnh dịch tễ học ung thư hiện nay tại TP Hồ Chí Minh và các tỉnh phía nam. 1995. Đặc san KHKT chào mừng 20 năm giải phóng miền Nam-10 năm thành lập trung tâm ung bướu; 1995.
6. Shields JA, Sheild CL. Duane’s Ophthalmology: Genetics of Retinoblastoma. 2004.
7. Hoàng Thị Kim Khuyên. Đặc điểm hình ảnh và hiệu quả bước đầu điều trị u nguyên bào võng mạc bằng truyền hoá chất qua đường động mạch. Luận văn Thạc sĩ Y học; 2019.
8. Nguyễn Ngọc Trung. Nghiên cứu đột biến gene RB1 và mối liên quan đến đặc điểm lâm sàng trên bệnh nhân u nguyên bào võng mạc. Luận án tiến sĩ Y học; 2019.
9. Gobin YP. Technique of Ophthalmic Artery Chemosurgery for Retinoblastoma. Recent Advances in Retinoblastoma Treatment. Springer; 2015.
10. Gobin YP, Dunkel IJ, Marr BP, Brodie SE, Abramson DH. Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience. Arch Ophthalmol. 2011;129(6):732-737. doi:doi:10.1001/archophthalmol.2011.5
11. Abramson DH, Beaverson K, Sangani P, et al. Screening for retinoblastoma: presenting signs as prognosticators of patient and ocular survival. Pediatrics. 2003;112(6):1248-1255. doi:doi:10.1542/peds.112.6.1248
12. Yang HK, Kim JH, Choung HK, Kim SJ, Yu YS. Combination of Chemotherapy and Transpupillary Thermotherapy for Retinoblastoma. J Korean Ophthalmol Soc. 2008;49(10):1619-1628.
13. Shields CL. Thermotherapy for Retinoblastoma. Arch Ophthalmol. 1999;117(7):885-893.